Study of effect of Nigella sativa on prevention of nephrotoxicity induced by colistin in experimental animals
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20190151Keywords:
Colistin, Nephrotoxicity, Nigella sativa oil, Oxidative stressAbstract
ABSTRACT
Background: Nigella sativa, a widely used medicinal plant throughout the world belongs to family ranunculaceae. Its Seeds and oil have a long history of folklore usage in various traditional systems of medicines and food. This study was performed to evaluate the protective effect of Nigella sativa oil (NSO) on kidney when simultaneously given with colistin sulfate (CS) which induces tubular damage in rats.
Methods: Animals were treated for 7 days: Group I (n=6) with normal saline and CMC, Group II, III and IV with 300.000IU/kg/day of CS (n=6). Group III and Group IV with NSO at the dose of 1 and 2ml/kg per orum prior to CS administration. All the animals were sacrificed on 8th day. Afterwards, the plasma creatinine (pCr), blood urea, renal tissue level of malondialdehyde (MDA), reduced glutathione (GSH) and renal histology were performed.
Results: Colistin sulfate induced tubular damage, increased the plasma creatinine (pCr), blood urea and MDA levels and decreased the reduced glutathione (GSH). However, simultaneous treatment with Nigella sativa oil at the dose of 1ml/kg and 2ml/kg for one week produced dose dependant improvement in tubular damage and reduced the biochemical alteration.
Conclusions: It could be concluded that, Colistin sulfate induced nephrotoxicity is ameliorated by NS oil especially in higher dose of (2ml/kg). This nephroprotective effect is ascribed to free radical scavenging and potent antioxidant activity in Nigella sativa.
References
Michalopoulos AS, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin. 2008;24:377-91.
Michalopoulos AS, Tsiodras SK, Rellos Menzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multidrug resistant gram negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115-21.
Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug resistant gram negative bacterial infections. Clin Infect Dis. 2005;40:1333-41.
Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):1-7.
Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacother J Human Pharmacol Drug Ther. 2010;30(12):1279-91.
Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601.
Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535.
Ozkan G, Ulusoy S, Orem A, Alkanat M, Mungan S, Yulug E, et al. How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother. 2013;57(8):3463-9.
Azad MAK, Akter J, Rogers KL, Nation RL, Velkov T, Li J. Major pathways of polymyxin- induced apoptosis in rat kidney proximal tubular cells. Antimicrob Agents Chemother. 2015;59:2136-43.
Sindhi V, Gupta V, Sharma K, Bhatnagar S, Kumari R, Dhaka N. Potential applications of antioxidants - A review panel. J Pharm Res. 2013;7(9):828-35.
Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytotherapy Research. Int J Dev Pharmacol Toxicol Eva Nat Produ Derivati. 2003 Apr;17(4):299-305.
Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of Nigella sativa: A miracle herb Asian Pac J Trop Biomed. 2013 May 1;3(5):337-52.
Mansour MA, Nagi MN, El‐Khatib AS, Al‐Bekairi AM. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT‐diaphorase in different tissues of mice: a possible mechanism of action. Cell Biochem Func. 2002 Jun;20(2):143-51.
Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. International immunopharmacology. 2005 Dec 1;5(13-14):1749-70.
Badary OA, Taha RA, Gamal El-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. Drug and Chem Toxicol. 2003 Jan 1;26(2):87-98.
Yehuda S, Carasso RL. Modulation of learning, pain thresholds, and thermoregulation in the rat by preparations of free purified alpha-linolenic and linoleic acids: determination of the optimal omega 3-to-omega 6 ratio. Proceedings of the National Academy of Sciences. 1993 Nov 1;90(21):10345-9.
Laakso P, Voutilainen P. Analysis of triacylglycerols by silver‐ion high‐performance liquid chromatography‐atmospheric pressure chemical ionization mass spectrometry. Lipids. 1996 Dec;31(12):1311-22.
Russo GL. Dietary n- 6 and n- 3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol. 2009 Mar 15;77(6):937-46.
Ghlissi Z, Hakim A, Mnif H, Ayadi FM, Zeghal K, Rebai T, et al. Evaluation of colistin nephrotoxicity administered at different doses in the rat model. Renal failure. 2013 Sep 1;35(8):1130-5.
Buege JA, Aust SD. [30] Microsomal lipid peroxidation. InMethods in enzymology 1978 Jan;52:302-310. Academic Press.
Sinha AK. Colorimetric assay of catalase. Analytical biochemistry. 1972 Jun 1;47(2):389-94.
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.
Yousef JM, Chen G, Hill PA, Nation RL, Li J. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother. 2012;67:452-9.
Mendes CAC, Burdmann EA. Polymyxins: review with emphasis on nephrotoxicity. Rev Assoc Med Bras. 2009;55(6):752-9.
Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.
Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents. 2005;26(6):504-7.
Ozkan G, Ulusoy S, Orem A, Alkanat M, Mungan S, Yulug E, et al. How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother. 2013;57(8):3463-9.
